SCD-411

Multiple CDMOs secured significant contract manufacturing opportunities as regulatory bodies approved new indications for established drugs, particularly in oncology and rare diseases.

Celltrion receives European Commission approval for Stobocolo and Osenvelt, biosimilar versions of Prolia and Xgeva (denosumab), following successful Phase 3 trials demonstrating equivalence.

The European Commission has granted marketing authorization for Formycon's FYB203 (aflibercept) biosimilar, to be marketed as AHZANTIVE® and Baiama®.

A comprehensive analysis of global diabetic retinopathy clinical trials has been released, offering insights into trial distribution across G7 and E7 countries and various research phases.

The EMA's CHMP has issued a positive opinion for Celltrion's Eydenzelt, a biosimilar to aflibercept (Eylea), for treating retinal disorders.